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While blockade of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) T cell regulatory receptor has become a commonly
utilized strategy in the management of advanced melanoma, many questions remain regarding the use of this agent in
patient populations with autoimmune disease. We present a case involving the treatment of a patient with stage IV
melanoma and ulcerative colitis (UC) with anti-CTLA-4 antibody immunotherapy. Upon initial treatment, the
patient developed grade III colitis requiring tumor necrosis factor-alpha (TNF-α) blocking antibody therapy,
however re-treatment with anti-CTLA-4 antibody following a total colectomy resulted in a rapid complete
response accompanied by the development of a tracheobronchitis, a previously described extra-intestinal
manifestation of UC. This case contributes to the evolving literature on the use of checkpoint inhibitors in
patients also suffering from autoimmune disease, supports future clinical trials investigating the use of these
agents in patients with autoimmune diseases, and suggests that an understanding of the specific molecular
pathways involved in a patient’s autoimmune pathology may provide insight into the development of more
effective novel combinatorial immunotherapeutic strategies.
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Ipilimumab is a humanized IgG monoclonal antibody that
blocks the negative regulatory receptor CTLA-4 on the
surface of activated T cells [1]. While ipilimumab has been
demonstrated to effectively promote the activation of ef-
fector CD8+ T cells, recent studies have revealed this agent
to also deplete regulatory T cell populations which con-
tribute to the establishment of an immunotolerant tumor
microenvironment [2,3]. Almost 25 years after the CTLA-
4 gene was cloned, clinical studies showing ipilimumab to
significantly prolong overall survival in patients with ad-
vanced melanoma earned this agent FDA approval in
March of 2011 [4]. While ipilimumab has been associated
with a disease control rate of ~25%, treatment with this* Correspondence: hanks004@mc.duke.edu
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unless otherwise stated.agent has also been associated with a number of immune-
related adverse events including enterocolitis (30-33%),
dermatitis (40-43%), hepatitis (3-9%) and autoimmune
lymphocytic hypophysitis with anterior panhypopituitar-
ism (1-6%) [5,6]. As evidence that anti-CTLA-4 antibody
blockade effectively induces the activation of self-reactive
T cells in melanoma patients, studies have associated the
induction of autoimmune side-effects with clinical re-
sponse [7]. Due to the potential for inducing these auto-
immune side-effects, there is significant apprehension
regarding the use of this agent in patients with underlying
autoimmune disease [8]. Given these concerns, there is
limited information available regarding the administration
of ipilimumab in this clinical setting. A small number of
recent case reports have described the administration of
ipilimumab to patients with concomitant autoimmune
disorders, specifically multiple sclerosis, rheumatoid arth-
ritis, and ulcerative colitis without related exacerbation
[8,9]. Here, we wish to add to these reports by describingentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fully treated with ipilimumab immunotherapy. While this
patient initially developed grade III colitis following his
first dose of ipilimumab (3 mg/kg), he later established
a rapid complete response to re-treatment with ipilimumab
following a total colectomy. In addition, upon re-treatment
with the complete four dose regimen of ipilimumab follow-
ing the colectomy procedure, the patient manifested side-
effects consistent with hypophysitis, dermatitis, as well as
tracheobronchitis, a condition previously described to
occur more frequently in patients with inflammatory bowel
disease [10,11].
Case presentation
A 61-year-old male was initially diagnosed with a melan-
oma involving his left neck in 1991 and treated with a
parotidectomy and neck dissection followed by adjuvant
radiation therapy. In July 2009, he was diagnosed with
UC, initially treated with infliximab, a chimeric TNF-α
monoclonal antibody for 6 weeks and then transitioned
to a purine analogue, azathioprine. In May of 2012, he
presented with a second primary melanoma involving
his left jaw. After a whole body PET revealed no evi-
dence of metastatic disease he underwent a radical neck
dissection with pathology revealing invasive malignant
melanoma characterized by an ulcerated Clark Level 5
lesion with a Breslow thickness of 5.5 mm and 15 mitotic
figures/mm2. In August of 2012, PET CT re-staging
showed FDG-avid cervical lymph nodes concerning for re-
current disease and a left parotidectomy revealed a 1.8 cmFigure 1 Ipilimumab Treatment Course of Patient with UC. A. re-staging ch
initial dose of ipilimumab, (2) following first dose of ipilimumab and ipilimu
to re-treatment with ipilimumab, (4) complete disease resolution followinglymph node deposit of malignant melanoma. Surveillance
PET imaging in December 2012 demonstrated evidence of
further recurrence in bilateral cervical lymph nodes. A
right modified neck dissection was positive for 1 of 6
lymph nodes notable for a melanoma deposit up to a
diameter of 2 cm. Further surveillance PET CT imaging in
May 2013 showed an interval increase in metabolic ac-
tivity within the lesions in his neck, with additional
metastasis to his chest, manubrium, and T5 vertebra
(Figure 1A-1). Brain MRI was negative. Given his limited
treatment options at the time and after a thorough discus-
sion regarding the potential toxicities in the setting of
known UC, it was decided to pursue ipilimumab immuno-
therapy. Cycle 1 was initiated in June of 2013. Six weeks
later he was eventually hospitalized for steroid-refractory
colitis characterized by colonoscopy as a moderate colitis
with diffuse erosions, ulcerations, and pseudopolyps which
resolved with a single dose of infliximab therapy. Further
ipilimumab was held and the patient was followed for
an additional two months before he was re-admitted
for colitis and re-started on azathioprine and IV methyl-
prednisolone followed by a slow prednisone taper in
late September 2013. The patient did well until mid-
November 2013 when he experienced an episode of
acute abdominal pain prompting a diagnosis of colonic
perforation and an urgent laparoscopic colectomy.
Pathology showed extensive ulcerative colitis with evidence
of a sigmoid perforation. Notably, PET CT imaging follow-
ing his initial hospitalization showed an overall improve-
ment in the FDG avidity of multiple sites of melanomaest axial PET CT imaging of patient at different time points. (1) prior to
mab-induced grade III colitis, (3) following total colectomy and prior
a four-dose regimen of ipilimumab. B. Time line of clinical events.
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tures including the manubrium, right clavicle, and the T5
vertebral body (Figure 1A-2). After recovering from his
surgery and receiving two monthly denosumab injections
at 120 mg via subcutaneous delivery, he underwent add-
itional re-staging with a PET CT showing evidence of dis-
ease progression (Figure 1A-3). After extensive discussion
of potential toxicities including the development of procti-
tis and/or other autoimmune manifestations involving the
hepatobiliary tract such as primary sclerosing cholangitis
(PSC), it was determined in April of 2014 that re-induction
therapy with ipilimumab in the setting of a total colectomy
would be reasonable. He did well until 2 weeks after his
second dose of ipilimumab when he reported a grade I lim-
ited pruritic rash and persistent dry cough for which he
was started on mometasone inhaler and chlorphenir-
amine/hydrocodone. By five weeks into his ipilimumab
regimen, the patient reported the development of a dry
cough and two weeks following his fourth dose of therapy,
he reported extreme fatigue and a reduction in stamina.
Morning labs were drawn and found to be consistent with
anterior panhypopituitarism prompting the initiation of
hydrocortisone replacement therapy. Although his fatigue
improved dramatically, he continued to report a persistent
dry cough that was interfering with his sleep. His initial 4
week re-staging PET CT following therapy showed interval
complete resolution of prior hypermetabolic FDG activityFigure 2 Induction of Tracheobronchitis and Elevation in Absolute Lymph
A. PET CT evidence of ipilimumab-induced tracheobronchitis in a patient w
day in a UC patient undergoing ipilimumab immunotherapy. Arrows indicawithin the left level II cervical lymph node, the chest wall
nodule, and foci in his manubrium, right clavicular head
and T5 vertebral body (Figure 1A-4) with diminished FDG
activity in a right level IV lymph node. At that time he was
also found to have FDG activity along the length of the tra-
chea consistent with a tracheobronchitis (Figure 2A). With
this finding, he was placed on a 10 day prednisone taper
which completely resolved his cough. He continued on
monthly denosumab therapy until he underwent re-staging
in October 2014 demonstrating a complete response (CR)
to therapy.
Conclusion
We describe a patient with active ulcerative colitis who
underwent treatment with ipilimumab immunotherapy
for progressive stage IV melanoma due to limited treatment
alternatives. Though the patient experienced a life threaten-
ing exacerbation of his ulcerative colitis with administration
of ipilimumab, after a total colectomy the patient achieved
a marked response to ipilimumab immunotherapy and
is, to this date, without evidence of disease. While most
patients that ultimately obtain a CR in response to ipili-
mumab therapy at a dose of 3 mg/kg exhibit relatively
rapid objective responses, previous long-term follow-up
studies have found patients to require an average of 30
months before obtaining a technical CR [12]. Therefore,
this case report describes a rapid response to ipilimumabocyte Count Following Treatment of UC Patient with Ipilimumab.
ith UC (arrow). B. Absolute lymphocyte count (ALC) versus treatment
te ipilimumab dosing.
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initiating ipilimumab immunotherapy. While the patient
never exhibited any signs or symptoms of PSC, he did de-
velop tracheobronchitis and two additional immune-
related adverse events (irAE) including a grade I rash and
a grade III autoimmune endocrinopathy (anterior panhy-
popituitarism). The development of a grade III irAE in
conjunction with the development of a CR are consist-
ent with prior studies showing a statistically significant
association between irAEs and objective response to
ipilimumab therapy [12,13]. In addition, this patient
also demonstrated a significant increase in his absolute
lymphocyte count (ALC), a finding previously noted to
correlate with clinical response to ipilimumab
(Figure 2B) [14].
The development of a grade IV irAE in a UC patient re-
ceiving ipilimumab therapy substantiates previous con-
cerns regarding the use of CTLA-4 blockade in this
patient population and emphasizes the need for close clin-
ical monitoring of patients with autoimmune diseases
undergoing any form of immunotherapy. This report also
raises the concept of a prophylactic colectomy in patients
with active inflammatory bowel disease prior to undergo-
ing anti-CTLA-4 antibody therapy. While this approach
was discussed following his initial treatment with ipilimu-
mab and repeat hospitalizations for grade III colitis, this
was felt to be associated with an unacceptably high risk-
benefit ratio given the lack of available data of ipilimumab
efficacy in the setting of UC. We acknowledge that this is
a single patient experience and is not necessarily applic-
able to all UC patients that also carry a diagnosis of
advanced melanoma. However, given the ultimate out-
come of this case, we feel that such an approach
should be contemplated on a patient-by-patient basis.
It is tempting to speculate that the altered T cell nega-
tive regulatory pathways which have been previously
described in UC patients, such as those that modulate
the IL-10 receptor signaling pathway, serve to predis-
pose to anti-CTLA-4 antibody-mediated T cell activation
and enable a more potent anti-tumor immune response
[15]. Whether this patient harbors a genetic mutation that
directly impacts effector T cell function is currently un-
known. It is also not clear whether patients with specific
types of autoimmune disease are more likely to respond to
anti-CTLA-4 antibody therapy. Given the various molecu-
lar mechanisms that have been identified among patients
with the same clinical diagnosis, we hypothesize that
patient responses to CTLA-4 blockade are more likely
to associate with specific molecular alterations rather
than the clinically diagnosed autoimmune disease.
This case report serves to contribute to the limited lit-
erature describing the use of an immune checkpoint in-
hibitor in a patient with an active autoimmune disease
and advocates for future clinical trials investigating theseagents in this patient population in a controlled setting.
We also propose that an understanding of the molecular
mechanisms underlying the autoimmune disease of pa-
tients who have generated significant responses to anti-
CTLA-4 therapy could lead to the identification of novel
combinatorial immunotherapy regimens with enhanced
clinical efficacy.
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